EP Patent

EP1929995A1 — Anaplerotic therapy of Huntington disease and other polyglutamine diseases

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2008-06-11 · 18y expired

What this patent protects

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

USPTO Abstract

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1929995A1
Jurisdiction
EP
Classification
—
Expires
2008-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.